



**EISAI TO PRESENT LATEST DATA ON PERAMPANEL  
AT 72ND AMERICAN EPILEPSY SOCIETY ANNUAL MEETING**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa®) will be presented at the 72nd American Epilepsy Society Annual Meeting (AES 2018) to be held from November 30 to December 4, 2018 in New Orleans in the United States.

Nineteen poster presentations will be given by Eisai at AES 2018, including reports on the interim analysis results of a Phase III clinical study (Study 311) in pediatric patients aged 4 to less than 12 years as well as a presentation on sustained seizure-free status in the open-label extension phase of a Phase III clinical study (Study 307) in patients 12 years of age and older. Including Investigator Initiated Studies, more than 50 scientific posters on perampanel will be presented at AES 2018.

Perampanel is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. It is available in tablet form to be taken once daily, and a new oral suspension formulation has been approved and is being marketed in the United States. A highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation by targeting glutamate activity at AMPA receptors on postsynaptic membranes, it is approved in countries around the world as an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures, and primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. Furthermore, perampanel is also indicated for monotherapy and adjunctive use in the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older in the United States.

Eisai considers neurology including epilepsy, a therapeutic area of focus, and strives to deliver perampanel throughout the world in pursuit of our mission to provide “seizure freedom” to a greater number of patients living with epilepsy. Eisai seeks to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

**Major Poster Presentations for perampanel:**

<b>Abstract number</b>	<b>Abstract title</b>
<b>Abstract number: #1.196</b> Saturday December 1 Poster presentation: 12:00-18:00 Poster discussion: 12:00-14:00	Symptoms and Impacts in Epilepsy: Findings from Qualitative Patient Interviews
<b>Abstract number: #1.322</b> Saturday December 1 Poster presentation: 12:00-18:00 Poster discussion: 12:00-14:00	Safety and Efficacy of Long-Term Treatment with Perampanel in Japanese Adults With Partial-Onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-Clonic Seizures in a Real-World Setting

(continued on following page)

<b>Abstract number</b>	<b>Abstract title</b>
<b>Abstract number: #2.152</b> Sunday December 2 Poster presentation: 10:00-16:00 Poster discussion: 12:00-14:00	Inpatient Hospitalizations Rates in Patients Diagnosed with Epilepsy and Treated with Perampanel or Lacosamide
<b>Abstract number: #2.231</b> Sunday December 2 Poster presentation: 10:00-16:00 Poster discussion: 12:00-14:00	Early Intervention With Perampanel Prevents Chronic Epilepsy and Behavioral Abnormalities in the Lithium-Pilocarpine Rat Model of Status Epilepticus (SE)
<b>Abstract number: #2.245</b> Sunday December 2 Poster presentation: 10:00-16:00 Poster discussion: 12:00-14:00	Study 311: Safety and Efficacy of Adjunctive Perampanel (PER) in Patients Aged 4 to <12 Years With Partial-Onset Seizures (POS) With/Without Concomitant Enzyme-Inducing Antiepileptic Drugs (EIAEDs)
<b>Abstract number: #2.246</b> Sunday December 2 Poster presentation: 10:00-16:00 Poster discussion: 12:00-14:00	Population Pharmacokinetics (PK) and Exposure–Response Analyses of Adjunctive Perampanel in Pediatric Patients With Epilepsy
<b>Abstract number: #2.252</b> Sunday December 2 Poster presentation: 10:00-16:00 Poster discussion: 12:00-14:00	Adjunctive Perampanel (PER) and Myoclonic and Absence Seizures: Post hoc Analysis of Seizure Days and Seizure-Free days in Study 332
<b>Abstract number: #2.254</b> Sunday December 2 Poster presentation: 10:00-16:00 Poster discussion: 12:00-14:00	Study 410 Enrollment Update: Multicenter, Open-Label, Phase IV Study of Perampanel as Monotherapy or First Adjunctive Therapy in Patients Aged ≥12 Years With Partial-Onset or Primary Generalized Tonic-Clonic (PGTC) Seizures
<b>Abstract number: #2.255</b> Sunday December 2 Poster presentation: 10:00-16:00 Poster discussion: 12:00-14:00	Sustained Seizure-Free Status With Adjunctive Perampanel (PER) for Patients With Secondarily Generalized (SG) Seizures During an Open-Label Extension (OLEx): Study 307
<b>Abstract number: #2.256</b> Sunday December 2 Poster presentation: 10:00-16:00 Poster discussion: 12:00-14:00	Sustained Seizure-Free Status With Adjunctive Perampanel for Patients With Primary Generalized Tonic-Clonic (PGTC) Seizures During the Open-Label Extension (OLEx) Phase of Study 332
<b>Abstract number: #2.257</b> Sunday December 2 Poster presentation: 10:00-16:00 Poster discussion: 12:00-14:00	Efficacy and Safety of Adjunctive Perampanel (PER) 4 mg/day for the Treatment of Partial-Onset Seizures (POS): Pooled Analysis of Four Randomized Phase III Studies
<b>Abstract number: #2.259</b> Sunday December 2 Poster presentation: 10:00-16:00 Poster discussion: 12:00-14:00	Real-World Use and Clinical Characteristics of Patients Treated with Antiepileptic Drug Combinations With and Without Perampanel in the United States
<b>Abstract number: #2.282</b> Sunday December 2 Poster presentation: 10:00-16:00 Poster discussion: 12:00-14:00	Perampanel (PER) Inhibits All Subtypes of AMPA Receptors Without Affecting NMDA and Kainate Receptors
<b>Abstract number: #3.284</b> Monday December 3 Poster presentation: 8:00-14:00 Poster discussion: 12:00-14:00	Perampanel in Real-World Clinical Care of Patients With Epilepsy: Retrospective Phase IV Study 506 – Second Interim Analysis
<b>Abstract number: #3.285</b> Monday December 3 Poster presentation: 8:00-14:00 Poster discussion: 12:00-14:00	Retrospective, Phase IV study of Perampanel in Real-World Clinical Care of Patients With Epilepsy: Analysis of Adolescent Subgroup (Aged 12 to <18 Years)

(continued on following page)

<b>Abstract number</b>	<b>Abstract title</b>
<b>Abstract number: #3.286</b> Monday December 3 Poster presentation: 8:00-14:00 Poster discussion: 12:00-14:00	Study 506: Retrospective, Phase IV Study of Perampanel in Real-World Clinical Care of Patients With Epilepsy: Analysis of a Pediatric Subgroup (Aged <12 Years)
<b>Abstract number: #3.287</b> Monday December 3 Poster presentation: 8:00-14:00 Poster discussion: 12:00-14:00	Study 311: Safety and Efficacy of Adjunctive Perampanel in Younger (Aged 4 to <7 Years) and Older (7 to <12 Years) Pediatric Patients With Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS)
<b>Abstract number: #3.289</b> Monday December 3 Poster presentation: 8:00-14:00 Poster discussion: 12:00-14:00	Study 311: Safety and Efficacy of Adjunctive Perampanel in Pediatric Patients (Aged 4 to <12 Years) With Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS)
<b>Abstract number: #3.291</b> Monday December 3 Poster presentation: 8:00-14:00 Poster discussion: 12:00-14:00	Phase II, Open-Label Pharmacokinetic (PK) Study of Perampanel Oral Suspension as Adjunctive Therapy in Pediatric Patients (Aged ≥1 to <24 Months) With Epilepsy: Study 238 Design and Preliminary Safety Data

Media Inquiries:

Public Relations Department,

Eisai Co., Ltd.

+81-(0)3-3817-5120